ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Molecular Partners AG

Molecular Partners AG (MOLN)

5,36
-0,04
(-0,65%)
Fermé 15 Janvier 10:00PM
5,36
0,00
( 0,00% )
Avant marché: 1:37PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
5,36
Prix Achat
5,41
Prix Vente
5,76
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
5,36
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
36 354 297
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-14,78
Bénéfice par action (BPA)
-1,71
Chiffre d'affairess
7,04M
Bénéfice net
-61,98M

À propos de Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Schlieren, Che
Fondé
-
Molecular Partners AG est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker MOLN. Le dernier cours de clôture d'Molecular Partners était de US$5,36. Au cours de la dernière année, les actions de Molecular Partners ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Molecular Partners compte actuellement 36 354 297 actions en circulation. La capitalisation boursière d'Molecular Partners est de US$194,86 million. Molecular Partners a un ratio cours/bénéfice (ratio PE) de -14.78.

MOLN Dernières nouvelles

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the...

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a...

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin...

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data...

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

MOLN - Frequently Asked Questions (FAQ)

What is the current Molecular Partners share price?
The current share price of Molecular Partners is US$ 5,36
How many Molecular Partners shares are in issue?
Molecular Partners has 36 354 297 shares in issue
What is the market cap of Molecular Partners?
The market capitalisation of Molecular Partners is USD 194,86M
What is the 1 year trading range for Molecular Partners share price?
Molecular Partners has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Molecular Partners?
The price to earnings ratio of Molecular Partners is -14,78
What is the cash to sales ratio of Molecular Partners?
The cash to sales ratio of Molecular Partners is 130,17
What is the reporting currency for Molecular Partners?
Molecular Partners reports financial results in CHF
What is the latest annual turnover for Molecular Partners?
The latest annual turnover of Molecular Partners is CHF 7,04M
What is the latest annual profit for Molecular Partners?
The latest annual profit of Molecular Partners is CHF -61,98M
What is the registered address of Molecular Partners?
The registered address for Molecular Partners is WAGISTRASSE 14, SCHLIEREN, 8952
What is the Molecular Partners website address?
The website address for Molecular Partners is www.molecularpartners.com
Which industry sector does Molecular Partners operate in?
Molecular Partners operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
SGBXSafe and Green Holdings Corporation
US$ 1,05
(94,44%)
47,8M
TAOPTaoping Inc BVI
US$ 0,505
(68,33%)
2,51M
OMCCOld Market Capital Corporation
US$ 10,54
(67,04%)
5
VMARVision Marine Technologies Inc
US$ 2,23
(59,29%)
15,13M
HSDTHelius Medical Technologies Inc
US$ 0,9832
(42,08%)
15,51M
DYNXDynamix Corporation
US$ 5,01
(-48,88%)
1
NESRNational Energy Services Reunited Corporation
US$ 5,11
(-41,47%)
6
WNWMeiwu Technology Company Ltd
US$ 0,6299
(-33,69%)
827,1k
EBMTEagle Bancorp Montana Inc
US$ 10,01
(-31,90%)
6
HTLMHomesToLife Ltd
US$ 5,20
(-31,13%)
406
SGBXSafe and Green Holdings Corporation
US$ 1,05
(94,44%)
47,8M
GCTKGlucoTrack Inc
US$ 0,0973
(-20,25%)
18,64M
HSDTHelius Medical Technologies Inc
US$ 0,9832
(42,08%)
15,51M
VMARVision Marine Technologies Inc
US$ 2,23
(59,29%)
15,13M
WINTWindtree Therapeutics Inc
US$ 0,225
(-9,96%)
13,2M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées